Acquired haemophilia A following COVID-19 vaccine

Document Type

Journal Article

Publication Date

3-5-2025

Journal

BMJ case reports

Volume

18

Issue

3

DOI

10.1136/bcr-2024-263299

Keywords

COVID-19; Haematology (incl blood transfusion); Immunological products and vaccines; Medical management

Abstract

Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure. Both events were preceded by a COVID-19 mRNA booster vaccination. Laboratory data was significant for a prolonged activated partial thromboplastin time (aPTT) of 55 s which prompted a haematology consult. A further work-up revealed the presence of an acquired FVIII inhibitor correlating with a severely reduced activity level. Treatment was given to eradicate the inhibitor with steroids and cyclophosphamide, while a thorough investigation was initiated for possible causes. Prompt recognition of an acquired inhibitor is essential for timely management to control bleeding.

Department

School of Medicine and Health Sciences Resident Works

Link to Full Text

Share

COinS